Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

555
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
555
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

System for study of diverse cellular composition in alveolar rhabdomyosarcoma.

Scientific reports·2026
Same author

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

British journal of cancer·2026
Same author

A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study.

Clinical pharmacokinetics·2026
Same author

Development of an Active Chimeric IL13Rα2 ADC for Diffuse Intrinsic Pontine Glioma.

ImmunoTargets and therapy·2026
Same author

A Pax7::Foxo1 conditional mouse strain.

Skeletal muscle·2026
Same author

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.

Neuro-oncology pediatrics·2026

Related Experiment Video

Updated: Jul 17, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma.

Jin-Ah Kim1, Kenneth A Crawford2, Piero A Spada2

  • 1Children's Cancer Therapy Development Institute, 9025 NE Von Neumann Drive Ste 110, Hillsboro, OR, 97006, USA. jinah@cc-tdi.org.

Scientific Reports
|September 1, 2023
PubMed
Summary

Enoxacin and entinostat show promise as adjuvant therapies to improve remission durability in Ewing sarcoma (EWS). Enoxacin, an FDA-approved antibiotic, is proposed for further clinical investigation in EWS patients.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.1K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Related Experiment Videos

Last Updated: Jul 17, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.1K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Ewing sarcoma (EWS) is a rare bone and soft tissue cancer affecting adolescents and adults.
  • Relapsed EWS lacks effective standard treatment, and recent trials failed to improve survival with more chemotherapy drugs.
  • There is a critical need for novel therapeutic strategies to enhance remission durability in EWS.

Purpose of the Study:

  • To investigate non-chemotherapy adjuvant drug candidates for combination therapy in EWS.
  • To identify potential agents that can extend remission durability beyond standard chemotherapy.

Main Methods:

  • In vitro efficacy assessment using anchorage-dependent and anchorage-independent growth assays.
  • In vivo evaluation of drug candidates in EWS xenograft mouse models.
  • Screening of three novel adjuvant drug candidates in combination with chemotherapy.

Main Results:

  • Enoxacin and entinostat demonstrated the most significant efficacy as adjuvant therapies.
  • Both drugs showed effectiveness in long-term in vitro and in vivo studies.
  • Enoxacin, an FDA-approved antibiotic, and entinostat, an investigational agent, were identified as lead candidates.

Conclusions:

  • Enoxacin and entinostat are effective adjuvant drug candidates for Ewing sarcoma.
  • Enoxacin is proposed for further preclinical and clinical investigation due to its FDA approval and demonstrated efficacy.
  • Adjuvant therapy with enoxacin may offer a new strategy to improve outcomes for EWS patients.